News

GlobalData on MSN6d
GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients
GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...
FiercePharma4d
Regulatory tracker: FDA signs off on GSK's prefilled syringe version of ...
UPDATED: Monday, July 14 at 9:35 a.m. ET A GSK label expansion bid for respiratory syncytial virus vaccine Arexvy is under review at the FDA.
GSK seeks FDA nod for expanded use of RSV vaccine in adults
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...
Verywell Health on MSN5d
Not Enough Adults Are Getting the RSV Vaccine. Here's Why That Matters
“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...
Stocktwits on MSN6d
GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance
GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the ...
Zacks Investment Research on MSN6d
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...